Comparison of joint destruction between standard- and low-dose etanercept in rheumatoid arthritis from the Prevention of Cartilage Destruction by Etanercept (PRECEPT) study

Rheumatology (United Kingdom)

Volumn 51, Issue 12, 2012, Pages 2164-2169

  Tada, Masahiro ^a   Koike, Tatsuya ^a   Okano, Tadashi ^a   Sugioka, Yuko ^a   Wakitani, Shigeyuki ^a   Fukushima, Kenzo ^b   Sakawa, Akira ^c   Uehara, Kazunori ^d   Inui, Kentaro ^e   Nakamura, Hiroaki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Fujiidera Municipal Hospital   (Japan)

^c Osaka Juso Hospital   (Japan)

^d Daito Central Hospital   (Japan)

^e Higashisumiyoshi Morimoto Hospital   (Japan)

Author keywords

Anti tumour necrosis factor; Efficacy; Etanercept; Low dose treatment; Radiographic outcome; Radiographic progression; Randomized controlled trial; Rheumatoid arthritis; Safety; Total modified Sharp score

Indexed keywords

ETANERCEPT;

ADULT; ARTICLE; CALCULATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; JOINT DESTRUCTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MODIFIED TOTAL SHARP SCORE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OPEN STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; TREATMENT DURATION; VOMITING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CARTILAGE DISEASES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME;

EID: 84870323579     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes188     Document Type: Article

References (19)

1. Moreland LW, Baumgartner SW, Schiff MH et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
2. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Moreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999;130: 478-86.
4. Weinblatt ME, Kremer JM, Bankhurst AD et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340: 253-9.
5. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
6. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
7. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27: 261-3.
8. Prevoo ML, van't Hof MA, Kuper HH et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
9. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983;26: 1346-53.
10. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
11. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
12. Smolen JS, Breedveld FC, Schiff MH et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology 2003;42: 244-57.
13. Aletaha D, Nell VP, Stamm T et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
14. Wada T, Son Y, Ozaki Y, Nomura S, Iida H. Clinical and radiographic results from a 2-year comparison of once-weekly versus twice-weekly administration of etanercept in biologics-naive patients with rheumatoid arthritis. Mod Rheumatol 2012, Advance Access published 3 February 2012, doi: 10.1007/s10165-011-0591-8.
15. Weinblatt ME, Schiff MH, Ruderman EM et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 2008;58:1921-30.
16. Smolen JS, Ilivanova E, Hall S et al. Low disease activity or remission induction with etanercept 50 mg and methotrexate in moderately active rheumatoid arthritis: maintenance of response and safety of etanercept 50 mg, 25 mg, or placebo in combination with methotrexate in a randomized double-blind study. Arthritis Rheum 2011; 63(Suppl 10):Abstract L1.
17. Bostsios C, Furlan A, Ostuni P et al. Effects of low-dose etanercept in maintaining DAS-remisiion previously achieved with standard-dose in patinets with rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl 2): Abstract OP0012.
18. Raffeiner B, Botsios C, Sfriso P et al. Efficacy of low dose etanercept in maintaining clinical and radiological remission in rheumatoid arthritis. Ann Rheum Dis 2010; 69(Suppl 3): Abstract OP0147.
19. van der Heijde D, Landewe R, Klareskog L et al. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. Arthritis Rheum 2005;52:49-60.